Recent News

• 11.09.2026 - CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
• 11.08.2026 - CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
• 11.04.2026 - CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
• 11.02.2026 - CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
• 11.02.2026 - CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
• 10.19.2026 - CRISPR Therapeutics Announces Chief Financial Officer Transition
• 10.08.2026 - CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
• 10.02.2026 - CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
• 09.08.2026 - CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
• 08.28.2026 - CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

Recent Filings

• 11.02.2026 - 3 Initial statement of beneficial ownership of securities
• 11.02.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.02.2026 - EX-99.1 EX-99.1
• 11.02.2026 - 8-K Current report
• 10.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2026 - 3 Initial statement of beneficial ownership of securities